About HANSOH PHARMA Company

Our company is one of the leading pharmaceutical companies in China driven by R&D and innovation. We are committed to meeting patients' unmet medical needs and improving human health and welfare through continuous innovation. The company has established a leading position in some of the largest, fastest-growing treatment fields in China, including anti-tumor, anti-infective, central nervous system diseases and metabolic diseases, and has successfully transformed into an innovative biopharmaceutical company focused on developing and selling innovative drugs. By the end of the reporting period, the Group had been approved to market seven innovative drugs, all of which had been included in the national medical insurance catalogue. During the reporting period, the Group approved a total of 6 new products for marketing, including an innovative drug (including approval for 2 indications); 23 new declarations and clinical approvals were obtained, which are related to 10 innovative drugs. The sales revenue of innovative drugs and cooperative products was approximately RMB 68.65 billion, which rose to about 67.9% of revenue, and has become the core driving force for the sustainable growth of the company's performance.